Pulmonology

The once-daily, triple-drug inhaler therapy reported improvements in exacerbation rate and risk to first event.

Over 16 months, a greater rate of patients reported returning visits, proper inhaler use understadning, and overall satisfcation.

Infants whose mothers were exposed to carbon monoxide in the second and third trimester were at highest risk for reduced lung function when they were tested at 1 month of age.

The therapy showed reduction in nighttime resting heart rate comparable to that of beta blockers.

The hazard ratios for ozone measured at bone as a single pollutant showed statistically significant higher risks for development of asthma, allergic rhinitis and eczema.

An association between antibiotic treatment in infancy and development of atopic asthma in childhood suggests an immune-mediated effect.

Ambient air pollution has become one of the world's greatest killers. But physicians still differ on their involvement in fighting it.

One inhalation product can be effective as a single maintenance and reliever therapy for asthma.

AstraZeneca announced that the first of its 2 phase 3 trials of benralizumab for severe COPD failed to meet its primary efficacy endpoint.

Researchers found that even high-performing hospitals can reduce over-utilization in bronchiolitis using novel de-implementation strategies.

Study show blocking FOXM1 can reduce the activation of fibroblasts as well as the process of idiopathic pulmonary fibrosis (IPF) itself.

Rare Disease Report sat down with AdAlta CEO Sam Cobb to discuss the impetus for the redesign of AD-214, and what it means for those in the idopathic pulmonary fibrosis.

Adding an anti-muscarinic to inhaled corticosteroid reduces asthma exacerbations, but possibly not more than other combinations.

The discovery could have researchers reconsidering treatment routes for pediatric patients.

A Rare Pediatric Disease designation was granted by the U.S. FDA this morning to Cellectar Biosciences for CLR 131, intended for the treatment of neuroblastoma.

In total, 35% of all HCPs polled responded that the inhalation device is “highly important” when determining medication for a newly diagnosed, stable patient with COPD.

The 10,000-plus participant IMPACT study reported the triple-combination therapy fared better in exacerbation reduction than FF/VI or FF/UMEC.

At the most recent American Lung Association LUNGFORCE expo, RDR sat down with Carly Ornstein to discuss the new resources made available by the ALA to individuals affected by lung fibrosis.

This morning, Galapagos announced the design of its global Phase 3 program of GLPG1690 in patients with idiopathic pulmonary fibrosis (IPF).

Three lung function trajectory categories were linked to were to 75% of COPD cases in a same-aged patient group by age 53.

The device reduces ischemic time in lung transplantation while enabling longer, safe out-of-body time of the allograft.

The findings indicate the potential for a clinically meaningful improvement and stabilization of lung function.

Early this morning, Reviva Therapeutics announced that the U.S. Food and Drug Administration has granted orphan drug designation to its clinical stage drug candidate RP5063, in development for the treatment of idiopathic pulmonary fibrosis.

A component in inflammatory pathogenesis including airway inflammation could serve as a biomarker in non-eosinophilic asthma.

Many physicians suggest upping a child’s dose of inhaled corticosteroids at the first symptoms of an asthma flare-up, but more research suggests the increased dosage makes no difference.